dm+d

Unassigned

New Medicines

SonsuviAcute sensorineural hearing loss (ASNHL)

Information

Sonsuvi
New molecular entity
Auris Medical
Auris Medical

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

JNK mitogen-activated protein kinase inhibitor; blocks the propagation of pro-apoptotic events
Figures from the US suggest an annual incidence of 5 to 20 per 100,000, however it is thought that many cases may go unreported. Median age at presentation is around 40 to 54 years, and sex distribution is roughly equal [2].
Acute sensorineural hearing loss (ASNHL)
Intratympanic

Trial or other data

Mar 19Mar 19: HEALOS trial results published in Otology & Neurology [9].

Evidence based evaluations